Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows ...

CEO Dave Ricks said Friday that the company will make its planned GLP-1 weight-loss pill in the U.S. amid President Donald ...

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg ...

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, ...

Orforglipron, a new nonpeptide GLP-1 drug, may provide easier access for the treatment of Type 2 diabetes and obesity without ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight-loss drugs Ozempic and ...

Eli Lilly said its drugs showed no signs of live injury in the trial. This is welcome news for researchers after Pfizer ...

A DAILY weight loss pill that works like Ozempic has succeeded in a major clinical trial. Patients lost an average of a stone ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...